Salarius Pharmaceuticals LLC is using a fragment-based discovery approach to develop safer inhibitors of lysine-specific histone demethylase, an epigenetic target that is up-regulated in hormone-dependent cancers and essential in specific forms of acute myelogenous leukemia and Ewing's sarcoma.

According to the company, the molecules were designed to inhibit the target reversibly to improve the therapeutic window for efficacy vs. on-target hematological toxicity.